Overview
The Humanized Models of Disease (HMD) Core provides investigators humanized mouse models to effectively conduct translatable research in biomedicine. Humanized mouse models are particularly suited to the investigation of disease and development of therapeutics. The objective of Core service is to deliver standard BLT humanized mice, Wistar humanized mice (WH mice: BLT+ AAV cocktail), archiving/provision of tumor tissues-generation of patient-derived xenograft mice (PDX mice), and the development of primary organoid (tumor) tissue cultures. In late 2023, the Core is planning on expanding services to include ovarian, lung and breast cancer tissue for PDX and organoid culture systems.
Services
- Provision of 12 to 14-week BLT or WH mice using fetal tissue or cord blood derived CD34+ stem cells
- Provision of melanoma PDX mice using NSG.
- Testing of all mice for levels of reconstitution
- Transfer/invoice if mice have >20% human CD45+ lymphocytes engraftment
- Drafts of “grant friendly” text to describe models, grant budget units to include, and support letters
- Provision of advice on items needed per inclusion of fetal tissue in NIH proposals
Any work related to customized differentiation methods or research use of BLT or WH mice past 12-14 weeks will require collaboration and is outside the scope of Core services. Please reach out to learn more as several labs have added humanized mice into their protocols.
Equipment & Features
- Dedicated vivarium holding rooms for inoculation and experimentation with humanized and PDX mice
- Horiba ABX Micros ES 60 Hematology Analyzer
Disclaimer: Resources of the Humanized Models of Disease Core are only available to Wistar researchers and based on availability.
